Mallinckrodt to acquire Sucampo Pharmaceuticals for $1.2bn

This article was originally published here

Mallinckrodt has signed a deal to acquire US-based Sucampo Pharmaceuticals for about $1.2bn to add the latter’s constipation medication Amitiza (lubiprostone) and other commercial and development assets to its portfolio.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply